749 related articles for article (PubMed ID: 28258391)
1. Underlying mechanisms of HIV-1 latency.
Romani B; Allahbakhshi E
Virus Genes; 2017 Jun; 53(3):329-339. PubMed ID: 28258391
[TBL] [Abstract][Full Text] [Related]
2. Posttranscriptional Regulation of HIV-1 Gene Expression during Replication and Reactivation from Latency by Nuclear Matrix Protein MATR3.
Sarracino A; Gharu L; Kula A; Pasternak AO; Avettand-Fenoel V; Rouzioux C; Bardina M; De Wit S; Benkirane M; Berkhout B; Van Lint C; Marcello A
mBio; 2018 Nov; 9(6):. PubMed ID: 30425153
[TBL] [Abstract][Full Text] [Related]
3. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection.
Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV
Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407
[TBL] [Abstract][Full Text] [Related]
4. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents.
Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP
J Virol; 2017 May; 91(9):. PubMed ID: 28202759
[TBL] [Abstract][Full Text] [Related]
5. A broad drug arsenal to attack a strenuous latent HIV reservoir.
Stoszko M; Ne E; Abner E; Mahmoudi T
Curr Opin Virol; 2019 Oct; 38():37-53. PubMed ID: 31323521
[TBL] [Abstract][Full Text] [Related]
6. The Multifaceted Contributions of Chromatin to HIV-1 Integration, Transcription, and Latency.
De Crignis E; Mahmoudi T
Int Rev Cell Mol Biol; 2017; 328():197-252. PubMed ID: 28069134
[TBL] [Abstract][Full Text] [Related]
7. Therapeutics for HIV-1 reactivation from latency.
Sgarbanti M; Battistini A
Curr Opin Virol; 2013 Aug; 3(4):394-401. PubMed ID: 23810462
[TBL] [Abstract][Full Text] [Related]
8. Regulation of human immunodeficiency virus-1 latency and its reactivation.
Verdin E
Bull Mem Acad R Med Belg; 2008; 163(6):355-64; discussion 364-5. PubMed ID: 19445107
[TBL] [Abstract][Full Text] [Related]
9. The role of latency reversal agents in the cure of HIV: A review of current data.
Bashiri K; Rezaei N; Nasi M; Cossarizza A
Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
[TBL] [Abstract][Full Text] [Related]
10. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy.
Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR
PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648
[TBL] [Abstract][Full Text] [Related]
11. Ultrasensitive HIV-1 p24 Assay Detects Single Infected Cells and Differences in Reservoir Induction by Latency Reversal Agents.
Passaes CPB; Bruel T; Decalf J; David A; Angin M; Monceaux V; Muller-Trutwin M; Noel N; Bourdic K; Lambotte O; Albert ML; Duffy D; Schwartz O; Sáez-Cirión A
J Virol; 2017 Mar; 91(6):. PubMed ID: 28077644
[TBL] [Abstract][Full Text] [Related]
12. The Tat Inhibitor Didehydro-Cortistatin A Prevents HIV-1 Reactivation from Latency.
Mousseau G; Kessing CF; Fromentin R; Trautmann L; Chomont N; Valente ST
mBio; 2015 Jul; 6(4):e00465. PubMed ID: 26152583
[TBL] [Abstract][Full Text] [Related]
13. The Pathway To Establishing HIV Latency Is Critical to How Latency Is Maintained and Reversed.
Rezaei SD; Lu HK; Chang JJ; Rhodes A; Lewin SR; Cameron PU
J Virol; 2018 Jul; 92(13):. PubMed ID: 29643247
[TBL] [Abstract][Full Text] [Related]
14. Understanding HIV latency: the road to an HIV cure.
Dahabieh MS; Battivelli E; Verdin E
Annu Rev Med; 2015; 66():407-21. PubMed ID: 25587657
[TBL] [Abstract][Full Text] [Related]
15. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients.
Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V
Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416
[TBL] [Abstract][Full Text] [Related]
16. HIV latency.
Siliciano RF; Greene WC
Cold Spring Harb Perspect Med; 2011 Sep; 1(1):a007096. PubMed ID: 22229121
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Approaches to Eradicate Latent HIV-1 in Resting CD4+ T Cells.
Sluis-Cremer N
Curr Top Med Chem; 2016; 16(10):1191-7. PubMed ID: 26324046
[TBL] [Abstract][Full Text] [Related]
18. The multifactorial nature of HIV-1 latency.
Lassen K; Han Y; Zhou Y; Siliciano J; Siliciano RF
Trends Mol Med; 2004 Nov; 10(11):525-31. PubMed ID: 15519278
[TBL] [Abstract][Full Text] [Related]
19. The Molecular Biology of HIV Latency.
Khoury G; Darcis G; Lee MY; Bouchat S; Van Driessche B; Purcell DFJ; Van Lint C
Adv Exp Med Biol; 2018; 1075():187-212. PubMed ID: 30030794
[TBL] [Abstract][Full Text] [Related]
20. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy.
Ikeda T; Shibata J; Yoshimura K; Koito A; Matsushita S
J Infect Dis; 2007 Mar; 195(5):716-25. PubMed ID: 17262715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]